Creso Pharma Limited
COPHF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $11,909 | $7,012 | $4,360 | $4,329 |
| % Growth | 69.8% | 60.8% | 0.7% | – |
| Cost of Goods Sold | $3,389 | $13,197 | $10,536 | -$2,134 |
| Gross Profit | $8,520 | -$6,185 | -$6,176 | $6,463 |
| % Margin | 71.5% | -88.2% | -141.6% | 149.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5,264 | $0 | $0 | $6,214 |
| SG&A Expenses | -$223 | $6,281 | $5,900 | $1,997 |
| Sales & Mktg Exp. | $794 | $0 | $0 | $1,683 |
| Other Operating Expenses | -$3,619 | -$104 | $0 | $11,582 |
| Operating Expenses | -$3,842 | $6,177 | $5,900 | $13,579 |
| Operating Income | -$4,318 | -$12,362 | -$12,076 | -$7,491 |
| % Margin | -36.3% | -176.3% | -277% | -173.1% |
| Other Income/Exp. Net | -$2,890 | -$15,953 | -$13,545 | $332 |
| Pre-Tax Income | -$7,208 | -$28,315 | -$25,621 | -$7,159 |
| Tax Expense | -$7 | $4 | $2 | $0 |
| Net Income | -$24,127 | -$28,319 | -$25,623 | -$7,159 |
| % Margin | -202.6% | -403.9% | -587.7% | -165.4% |
| EPS | 7.8 | -7.8 | -10.04 | 10.018 |
| % Growth | 200% | 22.3% | -200.2% | – |
| EPS Diluted | 7.8 | -7.8 | -10.04 | 10.018 |
| Weighted Avg Shares Out | 0 | 3,633 | 2,551 | 1,463,482 |
| Weighted Avg Shares Out Dil | 0 | 3,633 | 2,551 | 1,463,482 |
| Supplemental Information | – | – | – | – |
| Interest Income | $364 | $315 | $49 | $35 |
| Interest Expense | $4,694 | $4,997 | $445 | $247 |
| Depreciation & Amortization | -$558 | $1,233 | $1,794 | $155 |
| EBITDA | -$3,072 | -$22,085 | -$23,383 | $5,765 |
| % Margin | -25.8% | -315% | -536.3% | 133.2% |